Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research investigated the design and synthesis of steroid-based compounds as aromatase inhibitors for breast cancer, finding that certain structural modifications significantly enhance their inhibitory potency.

This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This paper discusses a structure-based analysis to find new BRD4 inhibitors, identifying finasteride and amentoflavone as promising candidates for BET inhibition.

This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.

This study mapped potential targets and pathways for baicalin's action in androgenic alopecia, suggesting it may inhibit 5α-reductase and serve as an effective treatment ingredient.

This study found that the combination of cyproterone acetate and ethinyl estradiol improved hirsutism and acne in women, with SH 8.1041 showing significant results and both treatments being generally well-tolerated.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

Combining oral minoxidil and bicalutamide may help improve hair growth in adolescent girls.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.

This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.

This study reports that TFM-4AS-1, a selective androgen receptor modulator, promoted bone and muscle growth with reduced effects on reproductive organs in ovariectomized rats.

This case report describes a 54-year-old Saudi woman with systemic lupus erythematosus and severe alopecia, where conventional treatments were ineffective. When belimumab was ineffective, baricitinib led to significant improvement in her condition, suggesting further research is needed to evaluate baricitinib's role in managing SLE.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study found that baricitinib, a selective Janus kinase inhibitor, led to significantly improved scalp coverage in alopecia areata patients over 36 weeks compared to placebo, though adverse effects like acne and urinary tract infections were reported.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

This review discusses the potential role of a PADI3 gene variant in central centrifugal cicatricial alopecia among African-American women but reports no new clinical results.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

In this case report, a 77-year-old woman developed alopecia areata after discontinuing cemiplimab treatment for metastatic cutaneous squamous cell carcinoma, suggesting an immune-related adverse effect potentially linked to systemic immune activation.

This case report describes a 12-year-old boy with severe atopic dermatitis and comorbid alopecia areata who experienced complete hair regrowth and improved skin condition after 3 months of oral abrocitinib treatment, with no adverse reactions observed during a 1-year follow-up period.

In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.